search
Back to results

Study of Forceps Cannulation During ERCP (SOCCER)

Primary Purpose

Post-ERCP Acute Pancreatitis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Forceps
Sponsored by
Dartmouth-Hitchcock Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Post-ERCP Acute Pancreatitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

PRIMARY INCLUSION CRITERIA:

  • Patient consent
  • ERCP done on native papilla

SECONDARY INCLUSION CRITERIA:

  • Papilla in a diverticulum
  • Papilla on rim of a diverticulum
  • Difficult cannulation (5 attempts, 5 minutes, or 2 unintended PD wire passages)
  • Redundant tissue overlying papilla
  • Type 2, 3, or 4 papilla

Exclusion Criteria:

  • Prior ampullectomy
  • Known pregnancy, positive test, breastfeeding
  • Clinical contraindication to ERCP
  • Metal allergy
  • Prior sphincterotomy
  • Inability to follow protocol
  • <18 years old
  • Enrolled in another ERCP study
  • Biliary/PD stent in place

Sites / Locations

  • Dartmouth HealthRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Forceps Assisted Cannulation

No Forceps Assisted Cannulation

Arm Description

Patients will have a forceps assisted cannulation during their ERCPs.

Patients will not have a forceps assisted cannulation during their ERCPs.

Outcomes

Primary Outcome Measures

Number of Difficult Cannulation
A difficult cannulation will be defined as any cannulation that results in any of the following: 5 or more minutes, 5 or more cannulation attempts, or 2 or more unintentional pancreatic wire passages.

Secondary Outcome Measures

Number of Post-ERCP Pancreatitis (PEP)
The secondary outcome is PEP. Acute pancreatitis according to the Atlanta guidelines, is at least two of the following: abdominal pain consistent with pancreatitis, lipase or amylase greater than 3 times the upper limit of normal, radiographic evidence of pancreatitis on cross sectional imaging.

Full Information

First Posted
April 14, 2022
Last Updated
July 24, 2023
Sponsor
Dartmouth-Hitchcock Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05336630
Brief Title
Study of Forceps Cannulation During ERCP
Acronym
SOCCER
Official Title
SOCCER: Study Of forCeps Cannulation During ERcp
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 12, 2022 (Actual)
Primary Completion Date
April 2025 (Anticipated)
Study Completion Date
April 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dartmouth-Hitchcock Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
A difficult cannulation has been identified as one of the high risk factors for developing post-ERCP pancreatitis (PEP). The accessibility and morphology of the papilla influence the level of cannulation difficulty. The use of a forceps to assist in the cannulation is a demonstrated effective technique for cannulating papillae that are difficult to access. Thus, the objective of our study is to determine whether a forceps assisted cannulation leads to less difficult cannulation during ERCP. Because difficult cannulation is associated with increased risk of PEP, our study investigates whether the forceps assisted cannulation also reduces the incidence of PEP as a secondary outcome. Eligible patients who have consented will either be randomized to cannulation with forceps or cannulation with no forceps.
Detailed Description
Endoscopic retrograde cholangiopancreatography (ERCP), an invasive procedure that combines endoscopy and x-ray to treat issues with the bile and pancreatic ducts, carries a two to ten percent risk of causing post-ERCP pancreatitis (PEP) [1]. Because acute pancreatitis is a devastating inflammatory condition that leads to extensive morbidity and mortality, efforts to reduce the risk of PEP in patients undergoing ERCP would enhance patient outcomes and would decrease the economic burden in treating PEP nationwide [2-4]. A difficult cannulation has been identified as one of the high risk factors for developing PEP [5]. A study performed by Scandinavian Association for Digestive Endoscopy (SADE) determined that cannulations with five or more attempts, a duration of five minutes or longer, or two or more unintended pancreatic duct (PD) wire passages significantly increased one's risk for PEP [6]. Thus, SADE defined a difficult cannulation as any cannulation with at least one of the following conditions: five or more attempts, five or more minutes, or two or more unintended PD wire passages [6]. This classification of a difficult cannulation has been adopted and standardized by the European Society of Gastrointestinal Endoscopy [7]. Because no current guidelines defining a difficult cannulation exist from the American College of Gastroenterology or American Gastroenterological Association, the European Society of Gastrointestinal Endoscopy (ESGE) guidelines as gathered from the SADE study are the worldwide standardized definition of difficult cannulation. Difficult cannulations have been reported to occur at a frequency of 42 percent for all ERCP exams [8]. The morphology and accessibility of the papilla influence the level of difficulty. Some studies have indicated that different macroscopic appearances of the papilla result in varying cannulation difficulty levels. Based on a study gauging intraobserver and interobserver agreement to the macroscopic appearance of different papillae, papillae are categorized as: Type 1, normal appearing; Type 2, small; Type 3, protruding or pendulous; and Type 4, ridged or creased [9]. Haraldsson et al. found that Type 2 and Type 3 papillae were more difficult to cannulate [8]. Regardless of papilla type, the involvement of a trainee (a GI fellow) resulted in more difficult cannulations [8]. In addition, the presence of redundant tissue, such as periampullary diverticula-which occurs in up to 20 percent of patients undergoing ERCP-results in more challenging cannulations [10]. The use of a forceps to assist in the cannulation is a demonstrated effective technique for cannulating papillae that are difficult to access [10-12]. The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation [10]. Currently, no randomized controlled trials that detail to what extent a forceps facilitates cannulation exist. Thus, our study aims to determine whether a forceps assisted cannulation reduces the incidence of difficult cannulations and consequently PEP. The primary outcome is difficult cannulation after randomization. A difficult cannulation will be defined as any cannulation that results in any of the following: 5 or more minutes, 5 or more cannulation attempts, or 2 or more unintentional pancreatic wire passages. The secondary outcome is PEP. Acute pancreatitis according to the Atlanta guidelines, is at least two of the following: abdominal pain consistent with pancreatitis, lipase or amylase greater than 3 times the upper limit of normal, radiographic evidence of pancreatitis on cross sectional imaging [13]. The study intervention is the use of a forceps during the cannulation. Eligible patients who have consented will either be randomized to forceps assisted cannulation or no forceps used during cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. SOCCER plans to enroll 152 patients. All patients undergoing ERCP at Dartmouth-Hitchcock endoscopy will be approached and consented for this study. Medical records will be reviewed to see if they meet inclusion/exclusion criteria. Patients will be consented day of the procedure. We received an approved HIPAA Authorization Waiver because access to a patient's chart will be required to determine inclusion/exclusion criteria. Consent will be performed in the endoscopy pre-op area. During the standard of care ERCP, the patients will be randomized intraoperatively to either cannulation with forceps and cannulation with no forceps. Written informed consent will be reviewed and signed before any study related procedures are performed. Please note that the primary outcome refers to a difficult cannulation AFTER randomization when the secondary inclusion criteria has been met. For example, if the secondary inclusion criteria met is difficult cannulation, then the primary outcome would be if from that point forward there were a difficult cannulation. As such, a total cannulation time of 10 minutes would enable the patient to be eligible (the first 5 minutes means the cannulation is difficult) and would mean the subject met the primary outcome (the second 5 minutes means cannulation after randomization is difficult). However, a total cannulation time of 8 minutes means the patient is eligible for the study (first 5 minutes means the cannulation is difficult) but did not meet the primary outcome (after randomization, the cannulation was not difficult because it was only 3 minutes). In a sense, the "difficult cannulation clock" is reset after randomization. If the secondary inclusion criteria met instead is papilla location or type, then the patient is randomized immediately before the cannulation and the difficult cannulation clock starts then. Measurement of difficult cannulation starts immediately after randomization upon the doctor's first cannulation attempt following randomization. Randomization will occur in block format. Randomization assignments will be placed in sealed manila envelopes that will be opened at the time of randomization. Manila envelopes will be kept with the study coordinator. After consent, data will be collected before, during, and after the procedure. The primary outcome will be measured during the procedure, whereas the secondary outcome will be determined during the 5 day follow up call. The study coordinator, GI fellow, or attending physician will call the patient 5 days (+/- 2 days) post-procedure to determine whether the patient developed PEP. Though it is preferred to contact the patient, other methods (chart review, emergency contact, outside records) are acceptable for determining the secondary outcome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-ERCP Acute Pancreatitis

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomized to either ERCP with forceps assisted cannulation or ERCP with no forceps.
Masking
Participant
Masking Description
Patients will be unblinded to their treatment on the 5 (+/- 2) day follow-up call.
Allocation
Randomized
Enrollment
152 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Forceps Assisted Cannulation
Arm Type
Experimental
Arm Description
Patients will have a forceps assisted cannulation during their ERCPs.
Arm Title
No Forceps Assisted Cannulation
Arm Type
No Intervention
Arm Description
Patients will not have a forceps assisted cannulation during their ERCPs.
Intervention Type
Device
Intervention Name(s)
Forceps
Intervention Description
The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. Please note that for the explicit purpose of the study the forceps will be used to grab tissue and not take biopsies. The forceps may still be used to take biopsies if the physician believes it is indicated.
Primary Outcome Measure Information:
Title
Number of Difficult Cannulation
Description
A difficult cannulation will be defined as any cannulation that results in any of the following: 5 or more minutes, 5 or more cannulation attempts, or 2 or more unintentional pancreatic wire passages.
Time Frame
Baseline (during the ERCP)
Secondary Outcome Measure Information:
Title
Number of Post-ERCP Pancreatitis (PEP)
Description
The secondary outcome is PEP. Acute pancreatitis according to the Atlanta guidelines, is at least two of the following: abdominal pain consistent with pancreatitis, lipase or amylase greater than 3 times the upper limit of normal, radiographic evidence of pancreatitis on cross sectional imaging.
Time Frame
5 (+/- 2) days after ERCP

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: PRIMARY INCLUSION CRITERIA: Patient consent ERCP done on native papilla SECONDARY INCLUSION CRITERIA: Papilla in a diverticulum Papilla on rim of a diverticulum Difficult cannulation (5 attempts, 5 minutes, or 2 unintended PD wire passages) Redundant tissue overlying papilla Type 2, 3, or 4 papilla Exclusion Criteria: Prior ampullectomy Known pregnancy, positive test, breastfeeding Clinical contraindication to ERCP Metal allergy Prior sphincterotomy Inability to follow protocol <18 years old Enrolled in another ERCP study Biliary/PD stent in place
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Timothy B Gardner, MD MS
Phone
603-650-5261
Email
timothy.b.gardner@hitchcock.org
First Name & Middle Initial & Last Name or Official Title & Degree
Steven M Hadley, Jr., AB
Phone
6036533669
Email
steven.m.hadley.jr@hitchcock.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy B Gardner, MD MS
Organizational Affiliation
Dartmouth-Hitchcock Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dartmouth Health
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25406464
Citation
Thaker AM, Mosko JD, Berzin TM. Post-endoscopic retrograde cholangiopancreatography pancreatitis. Gastroenterol Rep (Oxf). 2015 Feb;3(1):32-40. doi: 10.1093/gastro/gou083. Epub 2014 Nov 17.
Results Reference
background
PubMed Identifier
9691932
Citation
Neoptolemos JP, Raraty M, Finch M, Sutton R. Acute pancreatitis: the substantial human and financial costs. Gut. 1998 Jun;42(6):886-91. doi: 10.1136/gut.42.6.886.
Results Reference
background
PubMed Identifier
8782497
Citation
Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Pheley AM. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996 Sep 26;335(13):909-18. doi: 10.1056/NEJM199609263351301.
Results Reference
background
PubMed Identifier
32493506
Citation
Elmunzer BJ, Serrano J, Chak A, Edmundowicz SA, Papachristou GI, Scheiman JM, Singh VK, Varadarajulu S, Vargo JJ, Willingham FF, Baron TH, Cote GA, Romagnuolo J, Wood-Williams A, Depue EK, Spitzer RL, Spino C, Foster LD, Durkalski V; SVI study group and the United States Cooperative for Outcomes Research in Endoscopy (USCORE). Correction to: Rectal indomethacin alone versus indomethacin and prophylactic pancreatic stent placement for preventing pancreatitis after ERCP: study protocol for a randomized controlled trial. Trials. 2020 Jun 3;21(1):471. doi: 10.1186/s13063-020-04458-0.
Results Reference
background
PubMed Identifier
15173799
Citation
Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004 Jun;59(7):845-64. doi: 10.1016/s0016-5107(04)00353-0. No abstract available.
Results Reference
background
PubMed Identifier
24628493
Citation
Halttunen J, Meisner S, Aabakken L, Arnelo U, Gronroos J, Hauge T, Kleveland PM, Nordblad Schmidt P, Saarela A, Swahn F, Toth E, Mustonen H, Lohr JM. Difficult cannulation as defined by a prospective study of the Scandinavian Association for Digestive Endoscopy (SADE) in 907 ERCPs. Scand J Gastroenterol. 2014 Jun;49(6):752-8. doi: 10.3109/00365521.2014.894120. Epub 2014 Mar 14.
Results Reference
background
PubMed Identifier
27299638
Citation
Testoni PA, Mariani A, Aabakken L, Arvanitakis M, Bories E, Costamagna G, Deviere J, Dinis-Ribeiro M, Dumonceau JM, Giovannini M, Gyokeres T, Hafner M, Halttunen J, Hassan C, Lopes L, Papanikolaou IS, Tham TC, Tringali A, van Hooft J, Williams EJ. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2016 Jul;48(7):657-83. doi: 10.1055/s-0042-108641. Epub 2016 Jun 14.
Results Reference
background
PubMed Identifier
31326385
Citation
Haraldsson E, Kylanpaa L, Gronroos J, Saarela A, Toth E, Qvigstad G, Hult M, Lindstrom O, Laine S, Karjula H, Hauge T, Sadik R, Arnelo U. Macroscopic appearance of the major duodenal papilla influences bile duct cannulation: a prospective multicenter study by the Scandinavian Association for Digestive Endoscopy Study Group for ERCP. Gastrointest Endosc. 2019 Dec;90(6):957-963. doi: 10.1016/j.gie.2019.07.014. Epub 2019 Jul 18.
Results Reference
background
PubMed Identifier
28588881
Citation
Haraldsson E, Lundell L, Swahn F, Enochsson L, Lohr JM, Arnelo U; Scandinavian Association for Digestive Endoscopy (SADE) Study Group of Endoscopic Retrograde Cholangio-Pancreaticography. Endoscopic classification of the papilla of Vater. Results of an inter- and intraobserver agreement study. United European Gastroenterol J. 2017 Jun;5(4):504-510. doi: 10.1177/2050640616674837. Epub 2016 Oct 17.
Results Reference
background
PubMed Identifier
25409044
Citation
Levenick JM, Gardner TB, Hussain ZH, Gordon SR. SpyBite-assisted biliary cannulation for intradiverticular papilla during ERCP. Endoscopy. 2014;46 Suppl 1 UCTN:E514. doi: 10.1055/s-0034-1377365. Epub 2014 Nov 19. No abstract available.
Results Reference
background
PubMed Identifier
31995819
Citation
Borahma M, Benelbarhdadi I, Berhili C, Lagdali N, Ajana FZ. Forceps-assisted technique: a new technique for difficult cannulation. Endoscopy. 2020 Jul;52(7):E247-E248. doi: 10.1055/a-1089-7418. Epub 2020 Jan 29. No abstract available.
Results Reference
background
PubMed Identifier
33780985
Citation
Murabayashi T. The forceps-assisted technique for difficult cannulation has been in widespread use since 1996. Endoscopy. 2021 Apr;53(4):457. doi: 10.1055/a-1288-0801. Epub 2021 Mar 29. No abstract available.
Results Reference
background
PubMed Identifier
27163588
Citation
Foster BR, Jensen KK, Bakis G, Shaaban AM, Coakley FV. Revised Atlanta Classification for Acute Pancreatitis: A Pictorial Essay. Radiographics. 2016 May-Jun;36(3):675-87. doi: 10.1148/rg.2016150097. Erratum In: Radiographics. 2019 May-Jun;39(3):912.
Results Reference
background

Learn more about this trial

Study of Forceps Cannulation During ERCP

We'll reach out to this number within 24 hrs